BÜHLMANN Laboratories Forms Global Partnership with Beckman
BÜHLMANN Laboratories AG Partners with Beckman Coulter
BÜHLMANN Laboratories AG, known for its high-quality in-vitro diagnostic products, has announced an exciting new collaboration with Beckman Coulter. This partnership aims to facilitate the worldwide distribution of the BÜHLMANN fCAL® turbo and fPELA® turbo assays. These assays will be integrated into Beckman Coulter's clinical chemistry analyzers, providing laboratories with advanced tools to enhance patient care and diagnostic precision.
Streamlining Laboratory Processes
The collaboration is set to streamline laboratory operations significantly. By employing the BÜHLMANN fCAL® turbo assay alongside the CALEX® Cap sample preparation device, laboratories can efficiently determine fecal inflammation and digestion markers. This integration allows laboratories to automate their workflows more comprehensively, thus reducing manual processes and potential errors.
The BÜHLMANN fCAL® turbo Assay
The FDA-cleared BÜHLMANN fCAL® turbo assay is designed specifically to measure fecal calprotectin levels, a critical marker for diagnosing inflammatory bowel disease (IBD). This test stands out for its rapid results and high-quality analytical performance. Clinical studies have validated its effectiveness in distinguishing between IBD and irritable bowel syndrome (IBS), showcasing its precision and reliability.
Technological Advancements in Diagnostics
With technological innovation at the forefront, the fCAL® turbo assay enables clinicians to obtain results promptly, thereby aiding timely diagnosis and treatment. This responsiveness can greatly influence patient management, particularly in conditions that require quick intervention.
The BÜHLMANN fPELA® turbo Assay
On the other hand, the FDA-exempt BÜHLMANN fPELA® turbo assay provides an automated method for quantifying pancreatic elastase in stool samples. This biomarker is crucial for diagnosing exocrine pancreatic insufficiency, particularly in patients with chronic pancreatitis. By measuring pancreatic elastase levels, clinicians can better assess pancreatic function and the overall health of their patients.
Improving Patient Outcomes
Both assays significantly improve clinical efficiency while ensuring reproducibility and precision in results. This partnership not only supports the ongoing demand for accurate diagnostic tools but also reflects BÜHLMANN's commitment to enhancing laboratory capabilities worldwide.
A Commitment to Excellence
Laurent Collignon, CEO of BÜHLMANN Laboratories AG, expressed the company’s enthusiasm for this collaboration. He emphasized how the BÜHLMANN fCAL® turbo assay is prepared to meet the increasing demands in laboratory settings, offering unmatched throughput and speed in obtaining results.
Support and Training for Seamless Integration
Collin Shaw, CEO of BUHLMANN Diagnostics Corp, added that the collaboration would enhance customer support and training. This commitment ensures that laboratory staff can seamlessly adopt and integrate these advanced assays into their daily operations, ultimately benefiting patient diagnostics.
About BÜHLMANN Laboratories AG
Founded in 1976, BÜHLMANN Laboratories AG is a mid-sized company based in Switzerland, dedicated to developing and distributing high-quality in-vitro diagnostics. With a global presence spanning over 60 distributors, BÜHLMANN focuses on providing specialized diagnostic solutions while prioritizing quality and innovation.
About BUHLMANN Diagnostics Corp
As the U.S. commercial affiliate of BÜHLMANN Laboratories AG, BUHLMANN Diagnostics Corp operates out of Amherst, NH, and is dedicated to offering superior sales and support services to clinical laboratories across the country.
Frequently Asked Questions
What is the purpose of the BÜHLMANN fCAL® turbo assay?
The BÜHLMANN fCAL® turbo assay is designed to measure fecal calprotectin, aiding in the diagnosis of inflammatory bowel disease (IBD).
How does the collaboration with Beckman Coulter benefit laboratories?
This collaboration streamlines laboratory workflows by facilitating the automated integration of BÜHLMANN assays into Beckman Coulter's analyzers.
What is the role of pancreatic elastase in diagnosis?
Pancreatic elastase is a biomarker used to assess pancreatic function and is crucial for diagnosing exocrine pancreatic insufficiency.
Where is BÜHLMANN Laboratories AG located?
BÜHLMANN Laboratories AG is located in Schönenbuch, Switzerland, near Basel.
What kind of support will be provided to laboratories?
BUHLMANN Diagnostics Corp offers extensive training and support to facilitate the adoption of the new assays, ensuring laboratories can integrate them smoothly.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Exploring Global Heritage Initiatives and Their Impact
- Tensions Rise as Trump Plans Meeting with Ukraine's Zelenskyy
- MC Digital Realty Honored with Prestigious Company Award
- Investor Alert: Protect Your Rights with Kaspi.kz (NASDAQ: KSPI)
- Join the Spire Global Class Action: Know Your Rights Today!
- AvePoint Concludes Warrant Purchase Offer with Notable Results
- Municipal Emergency Services Expands Reach with Acquisition
- Lisa T. Miller Revolutionizes Healthcare Sales with New Podcast
- TransTech Group Expands Portfolio with CTR Acquisition
- Bridge Industries Enhances Portfolio with TransTech Acquisition
Recent Articles
- Bank of America Launches New Family Banking Account for Youth
- Understanding the P/E Ratio for Phillips 66: What It Means
- Growth Journey: How Grow Capital Reached Revenue Milestone
- Vocodia Holdings Appoints John Tabacco as Chairman Overseeing Media
- Hurricane Helene Disrupts Air Travel with Major Cancellations
- New York State's Strategic Shift to Sustainable Investments
- Celebrating Diversity: Barry Lawson Williams Received $10M Fund
- Tragic Incident: Four Lives Lost in Venezuelan Oil Barge Sinking
- Discover the Thrills of HellsGate Haunted House This October
- Citi Upgrades Sirius XM Price Outlook Amid Strategic Changes
- United Site Services Completes Successful Recapitalization Efforts
- Kepler Cheuvreux Endorses Ayvens SA with Buy Rating Amid Growth
- Innovative Instant Coffee Packaging Designed for Ease of Use
- Oppenheimer Boosts Apple Price Target Amidst Meta Competition
- Shawn Scholz Receives Advocacy Award for Financial Innovation
- Paratus Energy Services Reports Mandatory Trade Notification
- Challenges and Developments for P3 Health Partners Amid Market Drop
- Nature's New Season Unveils Wildlife Wonders Every Week
- Morgan Stanley Boosts Micron Technology's Outlook Significantly
- Support for New Gas Inventory Proposal Targeting Price Spikes
- JPMorgan Boosts DraftKings Price Target: Analyzing Competition
- Trade Notification Received by Paratus Energy Services Ltd.
- Pure Barre's Exciting Expansion Plans for Mexico City
- Blue Hill Advisors Elevates Bid for Territorial Bancorp Shares
- Amerant Bancorp's Strategic Moves for Long-Term Growth Plans
- Enlivex Therapeutics Advances Trials and Attracts Investor Interest
- BioAge Labs Launches Successful IPO With Strong Market Entry
- Bioage Labs IPO Surges on Opening Day With Better Pricing
- Mirion Technologies Receives Strong Buy Rating for Growth
- Natural Gas Producers Seek Clarity From Kamala Harris
- Spark Biomedical Ignites Medical Device Innovation with Fellowship
- Explore the Promising Future of the Medical Tourism Sector
- Projected Polyester Staple Fiber Market to Reach $58.6 Billion
- Alliance Trust PLC Makes Noteworthy Share Purchase Today
- Understanding the Decline of Armada Hoffler Properties Shares
- Proactis SA Financial Highlights and Future Outlook for 2024
- TAL Education Group: Riding The Wave of Economic Growth
- First Bank to Host Earnings Call: Key Insights and Details
- FTC Launches Operation AI Comply to Tackle Deceptive AI Firms
- First Bank Prepares for Q3 2024 Earnings Call on October 24
- How ON Semiconductor Turned $1,000 Into $8,000 in a Decade
- Turning $1000 into $10,000: The Amazing MARA Journey
- CCCC: A Game Changer for Crypto Influencers and Creators
- Exploring Options Trading Dynamics for Broadcom's Future
- Analyzing Recent Market Dynamics for KLA's Options Activity
- PepsiCo Options Show Smart Money's Strong Interest
- Jabil Sees Share Surge After Strong Earnings Report
- Milberg Initiates Class Action for Baltimore Bridge Business Losses
- Empowering Youth to Combat Hate-Fueled Violence in Society
- Alley Cat Allies Promises Reward to Combat Cat Cruelty